Kling Douglas F
Insider CIK 1699022 · NAMS Chief Operating Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2025-07-16 | 2025-07-17 | 51,043 | — | $0 | 162,702 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-07-16 | 2025-07-17 | 51,043 | $21.10 | $1.08M | 44,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2025-07-16 | 2025-07-17 | 51,043 | $10.90 | $556.4K | 95,043 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2025-07-15 | 2025-07-17 | 47,569 | — | $0 | 213,745 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-07-15 | 2025-07-17 | 3,544 | $22.12 | $78.4K | 44,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-07-15 | 2025-07-17 | 44,025 | $21.38 | $941.3K | 47,544 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2025-07-15 | 2025-07-17 | 47,569 | $10.90 | $518.5K | 91,569 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2025-06-16 | 2025-06-18 | 78,101 | — | $0 | 372,829 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2025-06-16 | 2025-06-18 | 21,899 | — | $0 | 261,314 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-06-16 | 2025-06-18 | 81,891 | $19.19 | $1.57M | 62,109 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-06-16 | 2025-06-18 | 18,109 | $19.75 | $357.7K | 44,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2025-06-16 | 2025-06-18 | 78,101 | $10.00 | $781.0K | 122,101 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2025-06-16 | 2025-06-18 | 21,899 | $10.90 | $238.7K | 144,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2025-05-15 | 2025-05-19 | 100,000 | — | $0 | 450,930 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-05-15 | 2025-05-19 | 100,000 | — | $0 | 44,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2025-05-15 | 2025-05-19 | 100,000 | $10.00 | $1.00M | 144,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2025-04-15 | 2025-04-17 | 100,000 | — | $0 | 550,930 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-04-15 | 2025-04-17 | 910 | — | $0 | 44,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-04-15 | 2025-04-17 | 99,090 | — | $0 | 44,910 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2025-04-15 | 2025-04-17 | 100,000 | $10.00 | $1.00M | 144,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2025-03-26 | 2025-03-28 | 16,539 | — | $0 | 0 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | A Award deriv | 2025-03-26 | 2025-03-28 | 16,539 | — | $0 | 16,539 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2025-03-26 | 2025-03-28 | 16,539 | — | $0 | 60,539 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-03-26 | 2025-03-28 | 16,539 | — | $0 | 44,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2025-03-17 | 2025-03-19 | 11,888 | — | $0 | 650,930 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2025-03-17 | 2025-03-19 | 88,112 | — | $0 | 47,251 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-03-17 | 2025-03-19 | 100,000 | — | $0 | 44,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2025-03-17 | 2025-03-19 | 88,112 | — | $0 | 132,112 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2025-03-17 | 2025-03-19 | 11,888 | $10.00 | $118.9K | 144,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2025-02-19 | 2025-02-20 | 9,218 | — | $0 | 126,145 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2025-02-19 | 2025-02-20 | 9,218 | — | $0 | 53,218 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-02-19 | 2025-02-20 | 9,218 | — | $0 | 44,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2025-02-18 | 2025-02-20 | 90,782 | — | $0 | 135,363 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-02-18 | 2025-02-20 | 90,782 | — | $0 | 44,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2025-02-18 | 2025-02-20 | 90,782 | — | $0 | 134,782 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2025-01-30 | 2025-01-31 | 13,578 | — | $0 | 226,145 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-01-30 | 2025-01-31 | 8,914 | — | $0 | 44,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-01-30 | 2025-01-31 | 4,664 | — | $0 | 52,914 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2025-01-30 | 2025-01-31 | 13,578 | — | $0 | 57,578 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2025-01-29 | 2025-01-31 | 56,863 | — | $0 | 239,723 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-01-29 | 2025-01-31 | 56,863 | — | $0 | 44,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2025-01-29 | 2025-01-31 | 56,863 | — | $0 | 100,863 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2025-01-28 | 2025-01-29 | 25,385 | — | $0 | 296,586 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2025-01-28 | 2025-01-29 | 25,385 | — | $0 | 69,385 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-01-28 | 2025-01-29 | 20,237 | — | $0 | 49,148 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-01-28 | 2025-01-29 | 5,148 | — | $0 | 44,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise deriv | 2025-01-27 | 2025-01-29 | 104,174 | — | $0 | 321,971 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | M Exercise | 2025-01-27 | 2025-01-29 | 104,174 | — | $0 | 148,174 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-01-27 | 2025-01-29 | 80,359 | — | $0 | 67,815 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | S Sale | 2025-01-27 | 2025-01-29 | 23,815 | — | $0 | 44,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | A Award | 2025-01-07 | 2025-01-07 | 44,000 | — | $0 | 44,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | A Award deriv | 2025-01-02 | 2025-01-06 | 250,000 | — | $0 | 250,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | A Award deriv | 2024-01-01 | 2024-01-03 | 323,771 | — | $0 | 323,771 | SEC↗ |